Intralesional and Perilesional Treatment of Skin Cancers

Arpey, Christopher J.; Annest, Nicole M.; Tucker, Stephen B.; Rapini, Ronald P.; MacFarlane, Deborah F.

doi:10.1007/978-0-387-88495-0_5

Cited by 3 publications

(4 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, scarring and onychodystrophy, hypopigmentation, Raynaud's phenomenon, anaphylaxis and flagellate hyperpigmentation have also been reported rarely (Arpey et al . ).…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

A pilot study on the use of ultra‐deformable liposomes containing bleomycin in the treatment of equine sarcoid

Knottenbelt

Watson

Hotchkiss

et al. 2018

Equine Veterinary Education

View full text Add to dashboard Cite

Summary The efficacy of a novel topical liposome‐encapsulated preparation of bleomycin (Bleosome) was studied in 118 clinical cases of equine sarcoid and efficacy was compared with two other standard conventional treatments, tazarotene and 5‐fluorouracil (5‐FU) as well as with the Bleosome in combination with each of these two conventional treatments. Treatments were arbitrarily assigned. Fifty‐two of the 118 sarcoids (44%) were resolved after 12 months but there were significant differences between treatment groups with the combinations of either 5‐FU and bleomycin, or tazarotene and bleomycin resulting in significantly superior resolution of 77 and 78% of the lesions, respectively. The preliminary results suggest that bleomycin in a liposomal carrier may be a useful treatment modality for superficial, diffuse and verrucose sarcoids. The treatment process was simple, and outcomes were functionally and cosmetically excellent. Liposome‐encapsulated bleomycin is economic compared to radiation and other treatment options and can be applied effectively by the owner under guidance. Further studies with different administration protocols and higher concentrations of bleomycin are warranted.

show abstract

“…Additionally, scarring and onychodystrophy, hypopigmentation, Raynaud's phenomenon, anaphylaxis and flagellate hyperpigmentation have also been reported rarely (Arpey et al . ).…”

Section: Discussionmentioning

confidence: 97%

“…Intralesional use of bleomycin also requires caution with inflammatory reactions reported in humans at the site of injection. Additionally, scarring and onychodystrophy, hypopigmentation, Raynaud's phenomenon, anaphylaxis and flagellate hyperpigmentation have also been reported rarely (Arpey et al 2010).…”

Section: Discussionmentioning

confidence: 99%

A pilot study on the use of ultra‐deformable liposomes containing bleomycin in the treatment of equine sarcoid

Knottenbelt

Watson

Hotchkiss

et al. 2018

Equine Veterinary Education

View full text Add to dashboard Cite

show abstract

“…Intralesional MTX has gained increased recognition for the treatment of solitary keratoacanthoma (KA), while limited studies have reported it for BCC treatment. 6 To address this knowledge gap, we evaluated the efficacy and safety of intralesional MTX as a convenient modality for BCC treatment and assess BCC histopathology before and after treatment. All patients were subjected to: Complete history taking, general examination of body systems to identify any associated medical conditions and a detailed dermatological examination; description of BCC site, size and subtype was recorded.…”

Section: Introductionmentioning

confidence: 99%

“…Methotrexate (MTX) has an appealing mechanism of action for the potential treatment of rapidly growing tumors; it inhibits DNA synthesis in actively dividing cells. Intralesional MTX has gained increased recognition for the treatment of solitary keratoacanthoma (KA), while limited studies have reported it for BCC treatment 6 …”

Section: Introductionmentioning

confidence: 99%

Clinicopathological evaluation of intralesional methotrexate in different subtypes of basal cell carcinoma

Khashaba

El-Garf

Hamed

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common malignant skin tumor. While slowly growing, it can cause major skin disfigurement. Therefore, novel cosmetically acceptable treatment options, other than surgery require investigation. The aim of the study was to evaluate efficacy and safety of intralesional methotrexate (MTX) as a convenient modality for BCC treatment clinically and pathologicaly. A total of 20 patients with BCC of any clinical variant underwent intralesional MTX injection at a maximum 1 mL of 25 mg/mL MTX per session. Histopathological assessments were performed before and 1 month after treatment. Forty percent of patients showed >50% clinical improvement after 1–4 sessions. Intralesional MTX is a suitable and safe treatment modality for BCC and may be used as an adjuvant to surgery.

show abstract

Making decisions on resectability and injectability status of lesions in the management of advanced melanoma in Germany, France and the UK

Fink¹,

Amelio

Harries

et al. 2016

European Journal of Dermatology

View full text Add to dashboard Cite

Intralesional and Perilesional Treatment of Skin Cancers

Cited by 3 publications

References 63 publications

A pilot study on the use of ultra‐deformable liposomes containing bleomycin in the treatment of equine sarcoid

A pilot study on the use of ultra‐deformable liposomes containing bleomycin in the treatment of equine sarcoid

Clinicopathological evaluation of intralesional methotrexate in different subtypes of basal cell carcinoma

Making decisions on resectability and injectability status of lesions in the management of advanced melanoma in Germany, France and the UK

Contact Info

Product

Resources

About